Autophosphorylation activation and inhibition by curcumin of the epidermal growth factor receptor reconstituted in liposomes

Journal of Molecular Recognition

Volumn 25, Issue 11, 2012, Pages 623-629

  Doumiati, Samah ^a   Haupt, Karsten ^a   Rossi, Claire ^a  

^a UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

Author keywords

autophosphorylation; curcumin; detergent removal; epidermal growth factor receptor; proteoliposomes; reconstitution; tyrosine kinase

Indexed keywords

CURCUMIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; LIGAND; LIPOSOME; PHOSPHATIDYLCHOLINE; PROTEIN TYROSINE KINASE;

BIOLOGICAL MODEL; CHEMISTRY; CONFERENCE PAPER; HUMAN; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION;

CURCUMIN; EPIDERMAL GROWTH FACTOR; HUMANS; LIGANDS; LIPOSOMES; MODELS, BIOLOGICAL; PHOSPHATIDYLCHOLINES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

CURCUMA LONGA;

EID: 84868143880     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.2194     Document Type: Conference Paper

References (46)

1. Anholt RR, Aebi U, Pedersen PL, Snyder SH,. 1986. Solubilization and reassembly of the mitochondrial benzodiazepine receptor. Biochemistry 25: 2120-2125.
2. Ariotti N, Liang H, Xu Y, Zhang Y, Yonekubo Y, Inder K, Du G, Parton RG, Hancock JF, Plowman SJ,. 2010. Epidermal growth factor receptor activation remodels the plasma membrane lipid environment to induce nanocluster formation. Mol. Cell. Biol. 30: 3795-3804.
3. Baselga J, Arteaga CL,. 2005. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 23: 2445-2459.
4. Boerner JL, Danielsen A, Maihle NJ,. 2003. Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm. Exp. Cell Res. 284: 111-121.
5. Bridges AJ,. 1999. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Curr. Med. Chem. 6: 825-843.
6. Brogden KA,. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3: 238-250.
7. Chen L, Merzlyakov M, Cohen T, Shai Y, Hristova K,. 2009. Energetics of ErbB1 transmembrane domain dimerization in lipid bilayers. Biophys. J. 96: 4622-4630.
8. Chung I, Akita R, Vandlen R, Toomre D, Schlessinger J, Mellman I,. 2010. Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature 464: 783-787.
9. Ciardiello F,. 2000. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 60 (Suppl 1): 25-32; discussion 41-42.
10. Daley GQ, Van Etten RA, Baltimore D,. 1990. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247: 824-830.
11. den Hartigh JC, van Bergen en Henegouwen PM, Boonstra J, Verkleij AJ,. 1993. Cholesterol and phosphoinositides increase affinity of the epidermal growth factor receptor. Biochim. Biophys. Acta 1148: 249-256.
12. Deniaud A, Rossi C, Berquand A, Homand J, Campagna S, Knoll W, Brenner C, Chopineau J,. 2007. Voltage-dependent anion channel transports calcium ions through biomimetic membranes. Langmuir 23: 3898-3905.
13. Dorai T, Gehani N, Katz A,. 2000. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. Mol. Urol. 4: 1-6.
14. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA,. 2003. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell 11: 507-517.
15. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu HJ, Walker F, Frenkel MJ, Hoyne PA, Jorissen RN, Nice EC, Burgess AW, Ward CW,. 2002. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110: 763-773.
16. Ge G, Wu J, Lin Q,. 2001. Effect of membrane fluidity on tyrosine kinase activity of reconstituted epidermal growth factor receptor. Biochem. Biophys. Res. Commun. 282: 511-514.
17. He L, Hristova K,. 2012. Physical-chemical principles underlying RTK activation, and their implications for human disease. Biochim. Biophys. Acta. 1818: 995-1005.
18. Heldin CH, Westermark B, Wasteson A,. 1979. Desensitisation of cultured glial cells to epidermal growth factor by receptor down-regulation. Nature 282: 419-420.
19. Herbst RS, Shin DM,. 2002. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94: 1593-1611.
20. Holloway PW,. 1973. A simple procedure for removal of Triton X-100 from protein samples. Anal. Biochem. 53: 304-308.
21. Ingolfsson HI, Koeppe RE, 2nd, Andersen OS,. 2007. Curcumin is a modulator of bilayer material properties. Biochemistry 46: 10384-10391.
22. Jaruga E, Salvioli S, Dobrucki J, Chrul S, Bandorowicz-Pikula J, Sikora E, Franceschi C, Cossarizza A, Bartosz G,. 1998. Apoptosis-like, reversible changes in plasma membrane asymmetry and permeability, and transient modifications in mitochondrial membrane potential induced by curcumin in rat thymocytes. FEBS Lett. 433: 287-293.
23. Ji C, Cao C, Lu S, Kivlin R, Amaral A, Kouttab N, Yang H, Chu W, Bi Z, Di W, Wan Y,. 2008. Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells. Cancer Chemother. Pharmacol. 62: 857-865.
24. Kim JH, Xu C, Keum YS, Reddy B, Conney A, Kong AN,. 2006. Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin. Carcinogenesis 27: 475-482.
25. Korutla L, Cheung JY, Mendelsohn J, Kumar R,. 1995. Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. Carcinogenesis 16: 1741-1745.
26. Korutla L, Kumar R,. 1994. Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells. Biochim. Biophys. Acta 1224: 597-600.
27. Levy D, Bluzat A, Seigneuret M, Rigaud JL,. 1990. A systematic study of liposome and proteoliposome reconstitution involving Bio-Bead-mediated Triton X-100 removal. Biochim. Biophys. Acta 1025: 179-190.
28. Mendelsohn J, Baselga J,. 2000. The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550-6565.
29. Mohammadi M, Honegger A, Sorokin A, Ullrich A, Schlessinger J, Hurwitz DR,. 1993. Aggregation-induced activation of the epidermal growth factor receptor protein tyrosine kinase. Biochemistry 32: 8742-8748.
30. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S,. 2002. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110: 775-787.
31. Panayotou GN, Magee AI, Geisow MJ,. 1985. Reconstitution of the epidermal growth factor receptor in artificial lipid bilayers. FEBS Lett. 183: 321-325.
32. Peschard P, Park M,. 2003. Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell 3: 519-523.
33. Raymond E, Faivre S, Armand JP,. 2000. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60 (Suppl 1): 15-23; discussion 41-42.
34. Rigaud J-L, Pitard B, Levy D,. 1995. Reconstitution of membrane proteins into liposomes: application to energy-transducing membrane proteins. Biochim. Biophys. Acta-Bioenergetics 1231: 223-246.
35. Rigaud JL, Levy D,. 2003. Reconstitution of membrane proteins into liposomes. Methods Enzymol. 372: 65-86.
36. Rigaud JL, Levy D, Mosser G, Lambert O,. 1998. Detergent removal by non-polar polysterene beads. Eur. Biophys. J. 27: 305-319.
37. Salomon DS, Brandt R, Ciardiello F, Normanno N,. 1995. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19: 183-232.
38. Stewart JC,. 1980. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal. Biochem. 104: 10-14.
39. Tranum-Jensen J, Christiansen K, Carlsen J, Brenzel G, Vinten J,. 1994. Membrane topology of insulin receptors reconstituted into lipid vesicles. J. Membr. Biol. 140: 215-223.
40. Ullrich A, Schlessinger J,. 1990. Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212.
41. Varkondi E, Schafer E, Bokonyi G, Gyokeres T, Orfi L, Petak I, Pap A, Szokoloczi O, Keri G, Schwab R,. 2005. Comparison of ELISA-based tyrosine kinase assays for screening EGFR inhibitors. J. Recept. Signal Transduct. Res. 25: 45-56.
42. Yao M, Shuin T, Misaki H, Kubota Y,. 1988. Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer. Cancer Res. 48: 6753-6757.
43. Yarden Y, Schlessinger J,. 1987a. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry 26: 1443-1451.
44. Yarden Y, Schlessinger J,. 1987b. Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. Biochemistry 26: 1434-1442.
45. Yarden Y, Ullrich A,. 1988. Growth factor receptor tyrosine kinases. Annu. Rev. Biochem. 57: 443-478.
46. Zhang J, Chen AP, Wang B, Zhao SP, Liu LZ, Dai SZ,. 2008. Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer. Ai Zheng 27: 1331-1336.